124 related articles for article (PubMed ID: 21489623)
1. NUP214-ABL1 positive T-cell acute lymphoblastic leukemia patient shows an initial favorable response to imatinib therapy post relapse.
Clarke S; O'Reilly J; Romeo G; Cooney J
Leuk Res; 2011 Jul; 35(7):e131-3. PubMed ID: 21489623
[No Abstract] [Full Text] [Related]
2. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia.
Graux C; Cools J; Melotte C; Quentmeier H; Ferrando A; Levine R; Vermeesch JR; Stul M; Dutta B; Boeckx N; Bosly A; Heimann P; Uyttebroeck A; Mentens N; Somers R; MacLeod RA; Drexler HG; Look AT; Gilliland DG; Michaux L; Vandenberghe P; Wlodarska I; Marynen P; Hagemeijer A
Nat Genet; 2004 Oct; 36(10):1084-9. PubMed ID: 15361874
[TBL] [Abstract][Full Text] [Related]
3. Complete morphologic and molecular remission after introduction of dasatinib in the treatment of a pediatric patient with t-cell acute lymphoblastic leukemia and ABL1 amplification.
Crombet O; Lastrapes K; Zieske A; Morales-Arias J
Pediatr Blood Cancer; 2012 Aug; 59(2):333-4. PubMed ID: 22689211
[TBL] [Abstract][Full Text] [Related]
4. ABL1 rearrangements in T-cell acute lymphoblastic leukemia.
Hagemeijer A; Graux C
Genes Chromosomes Cancer; 2010 Apr; 49(4):299-308. PubMed ID: 20073070
[TBL] [Abstract][Full Text] [Related]
5. Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia.
Grammatico S; Elia L; Peluso AL; Pedace L; Matarazzo M; Vitale A; Rago A; Pane F; Foà R; Cimino G
Leuk Res; 2009 Jul; 33(7):e73-4. PubMed ID: 19108887
[No Abstract] [Full Text] [Related]
6. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
7. Detection of a cryptic
Peterson JF; Pitel BA; Smoley SA; Smadbeck JB; Johnson SH; Vasmatzis G; Koon SJ; Webley MR; McGrath M; Bayerl MG; Baughn LB; Rowsey RA; Ketterling RP; Greipp PT; Hoppman NL
Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30936193
[TBL] [Abstract][Full Text] [Related]
8. T-cell acute lymphoblastic leukemia associated with complex karyotype and SET-NUP214 rearrangement: a case study and review of the literature.
Lee SG; Park TS; Cho SY; Lim G; Park GJ; Oh SH; Cho EH; Chong SY; Huh JY
Ann Clin Lab Sci; 2011; 41(3):267-72. PubMed ID: 22075511
[TBL] [Abstract][Full Text] [Related]
9. NUP214-ABL1 in adult T-ALL: the GMALL study group experience.
Burmeister T; Gökbuget N; Reinhardt R; Rieder H; Hoelzer D; Schwartz S
Blood; 2006 Nov; 108(10):3556-9. PubMed ID: 16873673
[TBL] [Abstract][Full Text] [Related]
10. Fusion of NUP214 to ABL1 on amplified episomes in T-ALL--implications for treatment.
Stergianou K; Fox C; Russell NH
Leukemia; 2005 Sep; 19(9):1680-1. PubMed ID: 16015385
[No Abstract] [Full Text] [Related]
11. ABL1 fusions in T-cell acute lymphoblastic leukemia.
De Keersmaecker K
Verh K Acad Geneeskd Belg; 2008; 70(4):245-55. PubMed ID: 19166098
[TBL] [Abstract][Full Text] [Related]
12. Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic
Stukaite-Ruibiene E; Norvilas R; Dirse V; Stankeviciene S; Vaitkeviciene GE
Pathol Oncol Res; 2022; 28():1610570. PubMed ID: 36172171
[TBL] [Abstract][Full Text] [Related]
13. Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib.
Defina M; Gozzetti A; Rondoni M; Aprile L; Ippoliti M; Chitarrelli I; Lauria F; Bocchia M
Leuk Res; 2010 Aug; 34(8):e215-6. PubMed ID: 20334915
[No Abstract] [Full Text] [Related]
14. What is the best salvage therapy for treatment of isolated CNS relapse in elderly patients with imatinib-responsive Ph(+) ALL?
Mele G; Pinna S; Melpignano A; Romano A; Brocca MC; Coppi MR; Quarta G
Leuk Res; 2007 Oct; 31(10):1445-7. PubMed ID: 17462730
[TBL] [Abstract][Full Text] [Related]
15. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Hoelzer D; Gökbuget N; Ottmann OG
Semin Hematol; 2002 Oct; 39(4 Suppl 3):32-7. PubMed ID: 12447850
[TBL] [Abstract][Full Text] [Related]
17. Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia.
Vanden Bempt M; Demeyer S; Broux M; De Bie J; Bornschein S; Mentens N; Vandepoel R; Geerdens E; Radaelli E; Bornhauser BC; Kulozik AE; Meijerink JP; Bourquin JP; de Bock CE; Cools J
Cancer Cell; 2018 Aug; 34(2):271-285.e7. PubMed ID: 30107177
[TBL] [Abstract][Full Text] [Related]
18. Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia.
Yamamoto M; Kakihana K; Kurosu T; Murakami N; Miura O
Cancer Genet Cytogenet; 2005 Mar; 157(2):104-8. PubMed ID: 15721630
[TBL] [Abstract][Full Text] [Related]
19. MRD analysis and treatment outcome in three children with SET-NUP214-positive hematological malignancies.
Li WJ; Cui L; Gao C; Zhao XX; Liu SG; Xing YP; Zhang RD; Zhang DW; Wang B; Li ZG; Wu MY
Int J Lab Hematol; 2011 Dec; 33(6):e25-7. PubMed ID: 21679311
[No Abstract] [Full Text] [Related]
20. Roots of clinical resistance to STI-571 cancer therapy.
Barthe C; Cony-Makhoul P; Melo JV; Mahon JR
Science; 2001 Sep; 293(5538):2163. PubMed ID: 11567109
[No Abstract] [Full Text] [Related]
[Next] [New Search]
